Global Pituitary cancer Market

Pituitary cancer Comprehensive Study by Type (Surgery, Endoscopic Transnasal Transsphenoidal Surgery, Craniotomy, Radiation Therapy, Stereotactic Radiosurgery, External beam radiation, Intensity Modulated Radiation Therapy (IMRT), Proton Beam Therapy, Chemotherapy, Others), Application (Hospital, Clinics, Diagnostic Centers, Research Institutes), Cancer (Adrenocorticotropic Hormone-Secreting (ACTH) Tumor, Growth Hormone-Secreting Tumor, Prolactin-Secreting Tumor, Thyroid-Stimulating Hormone-Secreting Tumor) Players and Region - Global Market Outlook to 2026

Pituitary cancer Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Pituitary cancer Market?

Pituitary cancer is a rare form of cancer and only a few hundred cases are recorded globally. This disease is identified in elderly population and 75% of the pituitary cancer cases are diagnosed after the death of the individual. As per the American Brain Tumor Association, benign tumor accounted for 30% to 40% of the total pituitary tumor cases. This tumor is mostly diagnosed in women and men aged between 40 years and 50 years. One from every four people is estimated to suffer from benign pituitary tumor (adenoma), which is non-cancerous. Most pituitary tumors are benign and treatable. Pituitary tumors account for 12% to 19% of the total primary brain tumors.

The market study is being classified by Type (Surgery, Endoscopic Transnasal Transsphenoidal Surgery, Craniotomy, Radiation Therapy, Stereotactic Radiosurgery, External beam radiation, Intensity Modulated Radiation Therapy (IMRT), Proton Beam Therapy, Chemotherapy and Others), by Application (Hospital, Clinics, Diagnostic Centers and Research Institutes) and major geographies with country level break-up.

Amgen Inc. (United States), Bristol-Myers Squibb Company (United States), Celgene Corporation (United States), Eli Lilly and Company (United States), Astellas Pharma Inc. (Japan), Merck & Co., Inc.(United States), Novartis AG (Switzerland), Pfizer Inc. (United States), AstraZeneca (United Kingdom), Mylan N.V. (United States), Johnson & Johnson Services, Inc. (United States) and Onxeo (France) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Ipsen Pharmaceuticals (France), Salix Pharmaceuticals, Inc. (United States) and Strides Pharma Science Limited (India).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Pituitary cancer market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Pituitary cancer market by Type, Application and Region.

On the basis of geography, the market of Pituitary cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Awareness regarding various Types of Cancer, including Pituitary Cancer
  • Growing Incidence Rate of Pituitary Cancer

Market Trend
  • Increasing R&D in the Field of Oncology

Restraints
  • Side Effects of the Treatment

Opportunities
  • Rising R&D Activities for the Development of Advanced Treatment Options
  • Increase in Ongoing Clinical Trials for Developing Treatment for Pituitary Cancer

Challenges
  • Stringent Government Regulations


On March 23, 2019, Corcept Therapeutics Incorporated announced a new website CushingResearch.com to support the recruitment in the phase 3 trial (called "GRACE") for Corcept’s proprietary compound relacorilant to treat the patients with Cushing’s syndrome., and On January 03, 2019, Cydan announced the launch of Tiburio Therapeutics Inc., which focused on developing treatments for rare neuroendocrine tumors and rare endocrine diseases


Key Target Audience
Biotechnology companies, Research institutes, Medical device companies, Pharmaceutical companies, Hospitals and clinics, Ambulatory surgical centers, Academic institutes and Government organizations

Report Objectives / Segmentation Covered

By Type
  • Surgery
  • Endoscopic Transnasal Transsphenoidal Surgery
  • Craniotomy
  • Radiation Therapy
  • Stereotactic Radiosurgery
  • External beam radiation
  • Intensity Modulated Radiation Therapy (IMRT)
  • Proton Beam Therapy
  • Chemotherapy
  • Others
By Application
  • Hospital
  • Clinics
  • Diagnostic Centers
  • Research Institutes
By Cancer
  • Adrenocorticotropic Hormone-Secreting (ACTH) Tumor
  • Growth Hormone-Secreting Tumor
  • Prolactin-Secreting Tumor
  • Thyroid-Stimulating Hormone-Secreting Tumor

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Awareness regarding various Types of Cancer, including Pituitary Cancer
      • 3.2.2. Growing Incidence Rate of Pituitary Cancer
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations
    • 3.4. Market Trends
      • 3.4.1. Increasing R&D in the Field of Oncology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pituitary cancer, by Type, Application, Cancer and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pituitary cancer (Value)
      • 5.2.1. Global Pituitary cancer by: Type (Value)
        • 5.2.1.1. Surgery
        • 5.2.1.2. Endoscopic Transnasal Transsphenoidal Surgery
        • 5.2.1.3. Craniotomy
        • 5.2.1.4. Radiation Therapy
        • 5.2.1.5. Stereotactic Radiosurgery
        • 5.2.1.6. External beam radiation
        • 5.2.1.7. Intensity Modulated Radiation Therapy (IMRT)
        • 5.2.1.8. Proton Beam Therapy
        • 5.2.1.9. Chemotherapy
        • 5.2.1.10. Others
      • 5.2.2. Global Pituitary cancer by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinics
        • 5.2.2.3. Diagnostic Centers
        • 5.2.2.4. Research Institutes
      • 5.2.3. Global Pituitary cancer by: Cancer (Value)
        • 5.2.3.1. Adrenocorticotropic Hormone-Secreting (ACTH) Tumor
        • 5.2.3.2. Growth Hormone-Secreting Tumor
        • 5.2.3.3. Prolactin-Secreting Tumor
        • 5.2.3.4. Thyroid-Stimulating Hormone-Secreting Tumor
      • 5.2.4. Global Pituitary cancer Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Pituitary cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celgene Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Astellas Pharma Inc. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc.(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan N.V. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Johnson & Johnson Services, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Onxeo (France)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Pituitary cancer Sale, by Type, Application, Cancer and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pituitary cancer (Value)
      • 7.2.1. Global Pituitary cancer by: Type (Value)
        • 7.2.1.1. Surgery
        • 7.2.1.2. Endoscopic Transnasal Transsphenoidal Surgery
        • 7.2.1.3. Craniotomy
        • 7.2.1.4. Radiation Therapy
        • 7.2.1.5. Stereotactic Radiosurgery
        • 7.2.1.6. External beam radiation
        • 7.2.1.7. Intensity Modulated Radiation Therapy (IMRT)
        • 7.2.1.8. Proton Beam Therapy
        • 7.2.1.9. Chemotherapy
        • 7.2.1.10. Others
      • 7.2.2. Global Pituitary cancer by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinics
        • 7.2.2.3. Diagnostic Centers
        • 7.2.2.4. Research Institutes
      • 7.2.3. Global Pituitary cancer by: Cancer (Value)
        • 7.2.3.1. Adrenocorticotropic Hormone-Secreting (ACTH) Tumor
        • 7.2.3.2. Growth Hormone-Secreting Tumor
        • 7.2.3.3. Prolactin-Secreting Tumor
        • 7.2.3.4. Thyroid-Stimulating Hormone-Secreting Tumor
      • 7.2.4. Global Pituitary cancer Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pituitary cancer: by Type(USD Million)
  • Table 2. Pituitary cancer Surgery , by Region USD Million (2015-2020)
  • Table 3. Pituitary cancer Endoscopic Transnasal Transsphenoidal Surgery , by Region USD Million (2015-2020)
  • Table 4. Pituitary cancer Craniotomy , by Region USD Million (2015-2020)
  • Table 5. Pituitary cancer Radiation Therapy , by Region USD Million (2015-2020)
  • Table 6. Pituitary cancer Stereotactic Radiosurgery , by Region USD Million (2015-2020)
  • Table 7. Pituitary cancer External beam radiation , by Region USD Million (2015-2020)
  • Table 8. Pituitary cancer Intensity Modulated Radiation Therapy (IMRT) , by Region USD Million (2015-2020)
  • Table 9. Pituitary cancer Proton Beam Therapy , by Region USD Million (2015-2020)
  • Table 10. Pituitary cancer Chemotherapy , by Region USD Million (2015-2020)
  • Table 11. Pituitary cancer Others , by Region USD Million (2015-2020)
  • Table 12. Pituitary cancer: by Application(USD Million)
  • Table 13. Pituitary cancer Hospital , by Region USD Million (2015-2020)
  • Table 14. Pituitary cancer Clinics , by Region USD Million (2015-2020)
  • Table 15. Pituitary cancer Diagnostic Centers , by Region USD Million (2015-2020)
  • Table 16. Pituitary cancer Research Institutes , by Region USD Million (2015-2020)
  • Table 17. Pituitary cancer: by Cancer(USD Million)
  • Table 18. Pituitary cancer Adrenocorticotropic Hormone-Secreting (ACTH) Tumor , by Region USD Million (2015-2020)
  • Table 19. Pituitary cancer Growth Hormone-Secreting Tumor , by Region USD Million (2015-2020)
  • Table 20. Pituitary cancer Prolactin-Secreting Tumor , by Region USD Million (2015-2020)
  • Table 21. Pituitary cancer Thyroid-Stimulating Hormone-Secreting Tumor , by Region USD Million (2015-2020)
  • Table 22. South America Pituitary cancer, by Country USD Million (2015-2020)
  • Table 23. South America Pituitary cancer, by Type USD Million (2015-2020)
  • Table 24. South America Pituitary cancer, by Application USD Million (2015-2020)
  • Table 25. South America Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 26. Brazil Pituitary cancer, by Type USD Million (2015-2020)
  • Table 27. Brazil Pituitary cancer, by Application USD Million (2015-2020)
  • Table 28. Brazil Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 29. Argentina Pituitary cancer, by Type USD Million (2015-2020)
  • Table 30. Argentina Pituitary cancer, by Application USD Million (2015-2020)
  • Table 31. Argentina Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 32. Rest of South America Pituitary cancer, by Type USD Million (2015-2020)
  • Table 33. Rest of South America Pituitary cancer, by Application USD Million (2015-2020)
  • Table 34. Rest of South America Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 35. Asia Pacific Pituitary cancer, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Pituitary cancer, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Pituitary cancer, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 39. China Pituitary cancer, by Type USD Million (2015-2020)
  • Table 40. China Pituitary cancer, by Application USD Million (2015-2020)
  • Table 41. China Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 42. Japan Pituitary cancer, by Type USD Million (2015-2020)
  • Table 43. Japan Pituitary cancer, by Application USD Million (2015-2020)
  • Table 44. Japan Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 45. India Pituitary cancer, by Type USD Million (2015-2020)
  • Table 46. India Pituitary cancer, by Application USD Million (2015-2020)
  • Table 47. India Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 48. South Korea Pituitary cancer, by Type USD Million (2015-2020)
  • Table 49. South Korea Pituitary cancer, by Application USD Million (2015-2020)
  • Table 50. South Korea Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 51. Taiwan Pituitary cancer, by Type USD Million (2015-2020)
  • Table 52. Taiwan Pituitary cancer, by Application USD Million (2015-2020)
  • Table 53. Taiwan Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 54. Australia Pituitary cancer, by Type USD Million (2015-2020)
  • Table 55. Australia Pituitary cancer, by Application USD Million (2015-2020)
  • Table 56. Australia Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Pituitary cancer, by Type USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Pituitary cancer, by Application USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 60. Europe Pituitary cancer, by Country USD Million (2015-2020)
  • Table 61. Europe Pituitary cancer, by Type USD Million (2015-2020)
  • Table 62. Europe Pituitary cancer, by Application USD Million (2015-2020)
  • Table 63. Europe Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 64. Germany Pituitary cancer, by Type USD Million (2015-2020)
  • Table 65. Germany Pituitary cancer, by Application USD Million (2015-2020)
  • Table 66. Germany Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 67. France Pituitary cancer, by Type USD Million (2015-2020)
  • Table 68. France Pituitary cancer, by Application USD Million (2015-2020)
  • Table 69. France Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 70. Italy Pituitary cancer, by Type USD Million (2015-2020)
  • Table 71. Italy Pituitary cancer, by Application USD Million (2015-2020)
  • Table 72. Italy Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 73. United Kingdom Pituitary cancer, by Type USD Million (2015-2020)
  • Table 74. United Kingdom Pituitary cancer, by Application USD Million (2015-2020)
  • Table 75. United Kingdom Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 76. Netherlands Pituitary cancer, by Type USD Million (2015-2020)
  • Table 77. Netherlands Pituitary cancer, by Application USD Million (2015-2020)
  • Table 78. Netherlands Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 79. Rest of Europe Pituitary cancer, by Type USD Million (2015-2020)
  • Table 80. Rest of Europe Pituitary cancer, by Application USD Million (2015-2020)
  • Table 81. Rest of Europe Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 82. MEA Pituitary cancer, by Country USD Million (2015-2020)
  • Table 83. MEA Pituitary cancer, by Type USD Million (2015-2020)
  • Table 84. MEA Pituitary cancer, by Application USD Million (2015-2020)
  • Table 85. MEA Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 86. Middle East Pituitary cancer, by Type USD Million (2015-2020)
  • Table 87. Middle East Pituitary cancer, by Application USD Million (2015-2020)
  • Table 88. Middle East Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 89. Africa Pituitary cancer, by Type USD Million (2015-2020)
  • Table 90. Africa Pituitary cancer, by Application USD Million (2015-2020)
  • Table 91. Africa Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 92. North America Pituitary cancer, by Country USD Million (2015-2020)
  • Table 93. North America Pituitary cancer, by Type USD Million (2015-2020)
  • Table 94. North America Pituitary cancer, by Application USD Million (2015-2020)
  • Table 95. North America Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 96. United States Pituitary cancer, by Type USD Million (2015-2020)
  • Table 97. United States Pituitary cancer, by Application USD Million (2015-2020)
  • Table 98. United States Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 99. Canada Pituitary cancer, by Type USD Million (2015-2020)
  • Table 100. Canada Pituitary cancer, by Application USD Million (2015-2020)
  • Table 101. Canada Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 102. Mexico Pituitary cancer, by Type USD Million (2015-2020)
  • Table 103. Mexico Pituitary cancer, by Application USD Million (2015-2020)
  • Table 104. Mexico Pituitary cancer, by Cancer USD Million (2015-2020)
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Pituitary cancer: by Type(USD Million)
  • Table 118. Pituitary cancer Surgery , by Region USD Million (2021-2026)
  • Table 119. Pituitary cancer Endoscopic Transnasal Transsphenoidal Surgery , by Region USD Million (2021-2026)
  • Table 120. Pituitary cancer Craniotomy , by Region USD Million (2021-2026)
  • Table 121. Pituitary cancer Radiation Therapy , by Region USD Million (2021-2026)
  • Table 122. Pituitary cancer Stereotactic Radiosurgery , by Region USD Million (2021-2026)
  • Table 123. Pituitary cancer External beam radiation , by Region USD Million (2021-2026)
  • Table 124. Pituitary cancer Intensity Modulated Radiation Therapy (IMRT) , by Region USD Million (2021-2026)
  • Table 125. Pituitary cancer Proton Beam Therapy , by Region USD Million (2021-2026)
  • Table 126. Pituitary cancer Chemotherapy , by Region USD Million (2021-2026)
  • Table 127. Pituitary cancer Others , by Region USD Million (2021-2026)
  • Table 128. Pituitary cancer: by Application(USD Million)
  • Table 129. Pituitary cancer Hospital , by Region USD Million (2021-2026)
  • Table 130. Pituitary cancer Clinics , by Region USD Million (2021-2026)
  • Table 131. Pituitary cancer Diagnostic Centers , by Region USD Million (2021-2026)
  • Table 132. Pituitary cancer Research Institutes , by Region USD Million (2021-2026)
  • Table 133. Pituitary cancer: by Cancer(USD Million)
  • Table 134. Pituitary cancer Adrenocorticotropic Hormone-Secreting (ACTH) Tumor , by Region USD Million (2021-2026)
  • Table 135. Pituitary cancer Growth Hormone-Secreting Tumor , by Region USD Million (2021-2026)
  • Table 136. Pituitary cancer Prolactin-Secreting Tumor , by Region USD Million (2021-2026)
  • Table 137. Pituitary cancer Thyroid-Stimulating Hormone-Secreting Tumor , by Region USD Million (2021-2026)
  • Table 138. South America Pituitary cancer, by Country USD Million (2021-2026)
  • Table 139. South America Pituitary cancer, by Type USD Million (2021-2026)
  • Table 140. South America Pituitary cancer, by Application USD Million (2021-2026)
  • Table 141. South America Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 142. Brazil Pituitary cancer, by Type USD Million (2021-2026)
  • Table 143. Brazil Pituitary cancer, by Application USD Million (2021-2026)
  • Table 144. Brazil Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 145. Argentina Pituitary cancer, by Type USD Million (2021-2026)
  • Table 146. Argentina Pituitary cancer, by Application USD Million (2021-2026)
  • Table 147. Argentina Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 148. Rest of South America Pituitary cancer, by Type USD Million (2021-2026)
  • Table 149. Rest of South America Pituitary cancer, by Application USD Million (2021-2026)
  • Table 150. Rest of South America Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 151. Asia Pacific Pituitary cancer, by Country USD Million (2021-2026)
  • Table 152. Asia Pacific Pituitary cancer, by Type USD Million (2021-2026)
  • Table 153. Asia Pacific Pituitary cancer, by Application USD Million (2021-2026)
  • Table 154. Asia Pacific Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 155. China Pituitary cancer, by Type USD Million (2021-2026)
  • Table 156. China Pituitary cancer, by Application USD Million (2021-2026)
  • Table 157. China Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 158. Japan Pituitary cancer, by Type USD Million (2021-2026)
  • Table 159. Japan Pituitary cancer, by Application USD Million (2021-2026)
  • Table 160. Japan Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 161. India Pituitary cancer, by Type USD Million (2021-2026)
  • Table 162. India Pituitary cancer, by Application USD Million (2021-2026)
  • Table 163. India Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 164. South Korea Pituitary cancer, by Type USD Million (2021-2026)
  • Table 165. South Korea Pituitary cancer, by Application USD Million (2021-2026)
  • Table 166. South Korea Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 167. Taiwan Pituitary cancer, by Type USD Million (2021-2026)
  • Table 168. Taiwan Pituitary cancer, by Application USD Million (2021-2026)
  • Table 169. Taiwan Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 170. Australia Pituitary cancer, by Type USD Million (2021-2026)
  • Table 171. Australia Pituitary cancer, by Application USD Million (2021-2026)
  • Table 172. Australia Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 173. Rest of Asia-Pacific Pituitary cancer, by Type USD Million (2021-2026)
  • Table 174. Rest of Asia-Pacific Pituitary cancer, by Application USD Million (2021-2026)
  • Table 175. Rest of Asia-Pacific Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 176. Europe Pituitary cancer, by Country USD Million (2021-2026)
  • Table 177. Europe Pituitary cancer, by Type USD Million (2021-2026)
  • Table 178. Europe Pituitary cancer, by Application USD Million (2021-2026)
  • Table 179. Europe Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 180. Germany Pituitary cancer, by Type USD Million (2021-2026)
  • Table 181. Germany Pituitary cancer, by Application USD Million (2021-2026)
  • Table 182. Germany Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 183. France Pituitary cancer, by Type USD Million (2021-2026)
  • Table 184. France Pituitary cancer, by Application USD Million (2021-2026)
  • Table 185. France Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 186. Italy Pituitary cancer, by Type USD Million (2021-2026)
  • Table 187. Italy Pituitary cancer, by Application USD Million (2021-2026)
  • Table 188. Italy Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 189. United Kingdom Pituitary cancer, by Type USD Million (2021-2026)
  • Table 190. United Kingdom Pituitary cancer, by Application USD Million (2021-2026)
  • Table 191. United Kingdom Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 192. Netherlands Pituitary cancer, by Type USD Million (2021-2026)
  • Table 193. Netherlands Pituitary cancer, by Application USD Million (2021-2026)
  • Table 194. Netherlands Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 195. Rest of Europe Pituitary cancer, by Type USD Million (2021-2026)
  • Table 196. Rest of Europe Pituitary cancer, by Application USD Million (2021-2026)
  • Table 197. Rest of Europe Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 198. MEA Pituitary cancer, by Country USD Million (2021-2026)
  • Table 199. MEA Pituitary cancer, by Type USD Million (2021-2026)
  • Table 200. MEA Pituitary cancer, by Application USD Million (2021-2026)
  • Table 201. MEA Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 202. Middle East Pituitary cancer, by Type USD Million (2021-2026)
  • Table 203. Middle East Pituitary cancer, by Application USD Million (2021-2026)
  • Table 204. Middle East Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 205. Africa Pituitary cancer, by Type USD Million (2021-2026)
  • Table 206. Africa Pituitary cancer, by Application USD Million (2021-2026)
  • Table 207. Africa Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 208. North America Pituitary cancer, by Country USD Million (2021-2026)
  • Table 209. North America Pituitary cancer, by Type USD Million (2021-2026)
  • Table 210. North America Pituitary cancer, by Application USD Million (2021-2026)
  • Table 211. North America Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 212. United States Pituitary cancer, by Type USD Million (2021-2026)
  • Table 213. United States Pituitary cancer, by Application USD Million (2021-2026)
  • Table 214. United States Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 215. Canada Pituitary cancer, by Type USD Million (2021-2026)
  • Table 216. Canada Pituitary cancer, by Application USD Million (2021-2026)
  • Table 217. Canada Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 218. Mexico Pituitary cancer, by Type USD Million (2021-2026)
  • Table 219. Mexico Pituitary cancer, by Application USD Million (2021-2026)
  • Table 220. Mexico Pituitary cancer, by Cancer USD Million (2021-2026)
  • Table 221. Research Programs/Design for This Report
  • Table 222. Key Data Information from Secondary Sources
  • Table 223. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pituitary cancer: by Type USD Million (2015-2020)
  • Figure 5. Global Pituitary cancer: by Application USD Million (2015-2020)
  • Figure 6. Global Pituitary cancer: by Cancer USD Million (2015-2020)
  • Figure 7. South America Pituitary cancer Share (%), by Country
  • Figure 8. Asia Pacific Pituitary cancer Share (%), by Country
  • Figure 9. Europe Pituitary cancer Share (%), by Country
  • Figure 10. MEA Pituitary cancer Share (%), by Country
  • Figure 11. North America Pituitary cancer Share (%), by Country
  • Figure 12. Global Pituitary cancer share by Players 2020 (%)
  • Figure 13. Global Pituitary cancer share by Players (Top 3) 2020(%)
  • Figure 14. Global Pituitary cancer share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 20. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 21. Celgene Corporation (United States) Revenue: by Geography 2020
  • Figure 22. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 24. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Astellas Pharma Inc. (Japan) Revenue: by Geography 2020
  • Figure 26. Merck & Co., Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 27. Merck & Co., Inc.(United States) Revenue: by Geography 2020
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 30. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 32. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 34. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 36. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2020
  • Figure 38. Onxeo (France) Revenue, Net Income and Gross profit
  • Figure 39. Onxeo (France) Revenue: by Geography 2020
  • Figure 40. Global Pituitary cancer: by Type USD Million (2021-2026)
  • Figure 41. Global Pituitary cancer: by Application USD Million (2021-2026)
  • Figure 42. Global Pituitary cancer: by Cancer USD Million (2021-2026)
  • Figure 43. South America Pituitary cancer Share (%), by Country
  • Figure 44. Asia Pacific Pituitary cancer Share (%), by Country
  • Figure 45. Europe Pituitary cancer Share (%), by Country
  • Figure 46. MEA Pituitary cancer Share (%), by Country
  • Figure 47. North America Pituitary cancer Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Amgen Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Celgene Corporation (United States)
  • Eli Lilly and Company (United States)
  • Astellas Pharma Inc. (Japan)
  • Merck & Co., Inc.(United States)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • AstraZeneca (United Kingdom)
  • Mylan N.V. (United States)
  • Johnson & Johnson Services, Inc. (United States)
  • Onxeo (France)
Additional players considered in the study are as follows:
Ipsen Pharmaceuticals (France) , Salix Pharmaceuticals, Inc. (United States) , Strides Pharma Science Limited (India)
Select User Access Type

Key Highlights of Report


May 2021 237 Pages 94 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pituitary cancer Market Quantitative research analysis
Global Pituitary cancer Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Awareness regarding various Types of Cancer, including Pituitary Cancer " is seen as one of major growth factors of Pituitary cancer Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Pituitary cancer Market Report?

Have a Query? Click Here

Other Related Reports

Chronic Traumatic Encephalopathy (CTE) Comprehensive Study by Type (Medical Treatment, Physical Therapy), Application (Athletes, Military Veterans, Other), End Users (Hospital & Clinic, Diagnostic Ce...
$ 3650
Progressive Multifocal Leukoencephalopathy Treatment Comprehensive Study by Type (Anti-Retroviral Therapy, Antiviral/Anti JCV, Other Symptomatic), Application (Hospital Pharmacies, Drug Stores, Retai...
$ 3750
Duodenal Ulcer Treatment Comprehensive Study by Type (True gastric ulcers, Combined gastric and duodenal ulcers., Suprapyloric and pyloric ulcers, Multiple ulcers of the stomach, Secondary gastric ul...
$ 3750
Rheumatology Drugs Comprehensive Study by Type (Disease Modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others), Application (Hospital Pharmacy...
$ 3750
Bariatric Surgeries Comprehensive Study by Type (Assisting (Suturing, Closure), Implantable (Gastric Bands, Electrical Stimulation)), End-users (Hospitals, Clinics, Others), Surgery Type (Invasive, N...
$ 3500
Hypocalcaemia Treatment Comprehensive Study by Type (Asymptomatic, Symptomatic, Prophylactic), Drug Type (Radiocontrast, Loop diuretics, Calcium supplements, Antibiotics, Antiepileptic drugs, Estroge...
$ 3450